论文部分内容阅读
目的探讨联合应用布地奈德混悬液和复方异丙托溴铵溶液治疗急性加重期慢性阻塞性肺疾病的效果。方法对2012年3月-2014年2月我院收治的102例急性加重期慢性阻塞性肺疾病患者的临床资料进行回顾性分析,根据入院的前后顺序将其分为A、B两组,每组各51例患者。为B组患者采用复方异丙托溴铵溶液进行治疗,为A组患者联合应用吸入用布地奈德混悬液和复方异丙托溴铵溶液进行治疗,并对比两组患者在进行治疗前后肺功能指标的变化及发生不良反应的情况。结果在进行治疗前,两组患者FVC、FEV1及FEV1/FVC的指标相比较差异不显著,无统计学意义(P>0.05)。与进行治疗前相比,两组患者在进行治疗后其FVC、FEV1及FEV1/FVC的指标较高,差异显著,有统计学意义(P<0.05)。与B组患者相比,A组在进行治疗后其FVC、FEV1及FEV1/FVC的指标较高,差异显著,有统计学意义(P<0.05)。在进行治疗期间,两组患者均未发生严重的不良反应。A组患者不良反应的发生率为19.61%,B组患者不良反应的发生率为13.73%,二者相比差异不显著,无统计学意义(P>0.05)。结论对急性加重期COPD患者联合应用布地奈德混悬液和复方异丙托溴铵溶液进行雾化吸入治疗的效果确切,可有效改善其肺功能,而且安全性较高,此法值得在临床上推广应用。
Objective To investigate the effect of combination of budesonide suspension and compound ipratropium bromide in the treatment of acute exacerbation chronic obstructive pulmonary disease. Methods The clinical data of 102 patients with acute exacerbation of chronic obstructive pulmonary disease admitted from March 2012 to February 2014 in our hospital were retrospectively analyzed. According to the order of admission, they were divided into A and B groups, Group of 51 patients. The patients in group B were treated with compound ipratropium bromide solution. Patients in group A were treated with inhalation of budesonide suspension and compound ipratropium bromide solution. Patients in both groups were compared before and after treatment with lung Changes in functional indicators and the occurrence of adverse reactions. Results Before treatment, there was no significant difference in the indexes of FVC, FEV1 and FEV1 / FVC between the two groups (P> 0.05). Compared with before treatment, the two groups of patients in the treatment of FVC, FEV1 and FEV1 / FVC indicators higher, the difference was statistically significant (P <0.05). Compared with patients in group B, the indexes of FVC, FEV1 and FEV1 / FVC were significantly higher in group A after treatment, with significant difference (P <0.05). During the treatment, no serious adverse reactions occurred in both groups. The incidence of adverse reactions in group A was 19.61%, and the incidence of adverse reactions in group B was 13.73%. There was no significant difference between the two groups (P> 0.05). Conclusions Inhaled inhalation of budesonide suspension and compound ipratropium bromide solution in patients with exacerbation of exacerbation of chronic obstructive pulmonary disease is effective in the treatment of inhaled aerosol, which can effectively improve pulmonary function and safety. This method is worthy of clinical application On the promotion of application.